CIRCIO HOLDING ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.85 NOK | -41.24% |
|
-47.99% | -60.42% |
| Apr. 17 | Circio Establishes In Vivo Proof-of-Concept for Circular RNA Platform | MT |
| Apr. 17 | Circio to Raise Up to NOK60 Million via Rights Issue | MT |
| Sales 2023 * | - | Sales 2024 * | 200M 18.24M | Capitalization | 21.7M 1.98M |
|---|---|---|---|---|---|
| Net income 2023 * | -102M -9.3M | Net income 2024 * | -1M -91.18K | EV / Sales 2023 * | - |
| Net cash position 2023 * | 23.58M 2.15M | Net cash position 2024 * | 169M 15.41M | EV / Sales 2024 * | -0.74 x |
| P/E ratio 2023 * |
-0.27
x | P/E ratio 2024 * |
0.49
x | Employees | 17 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 83.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Circio Holding ASA
More press releases
| 1 day | -41.24% | ||
| 1 week | -47.99% | ||
| Current month | -52.50% | ||
| 1 month | -52.50% | ||
| 3 months | -59.06% | ||
| 6 months | -70.16% | ||
| Current year | -60.42% |
1 week
2.41
5.48
1 month
2.418.00
Current year
2.418.10
1 year
2.4123.97
3 years
2.41288.00
5 years
2.41360.00
10 years
2.411 080.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 17-03-31 | |
Lubor Gaal
DFI | Director of Finance/CFO | 56 | 22-03-06 |
Thomas Hansen
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Diane Mellett
BRD | Director/Board Member | 64 | 15-09-13 |
Thomas Falck
BRD | Director/Board Member | 58 | 22-04-20 |
| Director/Board Member | 77 | 15-06-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 2.85 | -41.24% | 1,319,996 |
| 24-04-16 | 4.85 | -6.73% | 67,574 |
| 24-04-15 | 5.2 | -3.35% | 41,258 |
| 24-04-12 | 5.38 | -1.82% | 35,511 |
| 24-04-11 | 5.48 | 0.00% | 2,009 |
Real-time Oslo Bors, April 17, 2024 at 10:45 am EDT
More quotes
Circio Holding ASA, formerly Targovax ASA, is a Norway-based company active within the healthcare sector. The Company is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The Company offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circioâs second clinical program is an immunotherapy targeting KRAS driver mutations.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.85
NOK
Average target price
48
NOK
Spread / Average Target
+1,584.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.42% | 1.97M | |
| -3.39% | 102B | |
| +2.61% | 96.84B | |
| -1.02% | 21.48B | |
| -18.14% | 20.82B | |
| -6.87% | 18.6B | |
| -40.70% | 16.81B | |
| -26.89% | 13.78B | |
| +1.12% | 13.4B | |
| +22.25% | 11.06B |
- Stock Market
- Equities
- TRVX Stock
